News View All News arrow-button

Apr 10, 2018

IFM Therapeutics Nominated for Deal of the Year at the New England Venture Capital Association’s 2018 NEVY Awards

IFM Therapeutics has been nominated for “Deal/Exit of the Year” in the 2018 NEVY Awards, hosted by New England Venture Capital Association (NEVCA). The 6th annual NEVYs, celebrate New England’s top innovators, investors and companies across the region’s health care, life science and tech communities. 

IFM is receiving this nomination for its September 2017 deal with Bristol-Myers Squibb (BMS), which saw BMS acquire IFM’s preclinical STING and NLRP3 agonist programs. As part of the deal, IFM retained its current personnel, facilities and research programs—including an NLRP3 antagonist program focused on curbing immune responses that lead to inflammatory diseases and fibrosis—under the name IFM Therapeutics, LLC.   

The final winners will be announced at the NEVYs award ceremony on Wednesday, May 9 at Boston’s House of Blues.  

To join us, you can purchase tickets at 

Media Contact

Amanda Sellers
Spectrum Science Communications